Taking Pacific Edge as an example:
This has taken 6 years to get from initial acceptance of a Midkine marker into a Bladder Cancer Diagnostic test (along with others) to the actual nitty gritty of realtime commercial operation which produces royalties likely to become expotential for CDY
What we dont know is if 6 years is a long time, short time, (heaven forbid) or par for the course.
Other collaborations may be nearing commercial activity.
The need for two extra subsidiaries would indicate that something is getting close.
Evolis One ( a midkine product) in the US is the key to totally unlocking all the midkine potential.
- Forums
- ASX - By Stock
- AN1
- Ann: USA Distribution Partnership for Cellmid's Evolis-CDY.AX
Ann: USA Distribution Partnership for Cellmid's Evolis-CDY.AX, page-97
Featured News
Add AN1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AN1 (ASX) Chart |
Day chart unavailable